An interventional study of Treatment: Minoxidil 5% / Botanical Hair Solution for Men in Male Pattern of Hair Loss, Androgenic Alopecia, sponsored by Galderma R&D. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-08-01.
Sponsored by Galderma R&D (part of Galderma Group AG) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.
Among the 31 studies testing minoxidil in Alopecia, this one is the 14th largest by enrollment, is one of 3 that started in 2015, is one of 8 with no phase, and was the 7th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:
Kasr El Aini Hospital · Sites in Egypt
Ages 18–50 · Men only · Healthy volunteers
Shanghai Zhongshan Hospital · Sites in China
Ages 18–40 · Women only
Sohag University · Sites in Egypt
Ages 15–60 · Women only · Healthy volunteers
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+ · Women only
Eurofarma Laboratorios S.A. · Sites in Brazil
Ages 18–60 · Men only
By country, each count listing its studies:
Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →
Of the 74 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 46 (62%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 60 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 8 · Phase 4 3
First in 2003; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 60 across the 31 interventional studies. Of the 14 that completed or were terminated, 4 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
Galderma Group AG has 2 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
1 of the studies testing minoxidil in Alopecia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05778825Memorial Sloan Kettering Cancer CenterA Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing minoxidil in Alopecia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the effect of Minoxidil 5% Foam and Botanical Hair Solution Regimen in men with thinning hair and male pattern hair loss/androgenic alopecia (Norwood III \& IV).
Key Inclusion Criteria:
Key Exclusion Criteria:
3 Subjects taking or planning to take topical or systemic prescription or OTC medications for treating hair loss and/or hair volume.
Drug: Treatment: Minoxidil 5% / Botanical Hair Solution for Men
Drug page: Minoxidil
Change From Baseline in Investigator's Rating of Standardized Global Photographs at Week 12
The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale. Investigator global photograph rating were assessed using 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.
Time frame: At Week 12
Change From Baseline in Participant Rating at Week 12
Participants rated the parameters like appearance of hair, growth of hair, satisfaction with hairline at the front of the head, satisfaction with hair on the top of the head and satisfaction with hair overall as an overall improvement from the baseline by conducting their own assessments by looking in a mirror and evaluating improvement from baseline using a 1 to 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.
Time frame: At Week 12
Mean Change From Baseline in Shed Hair Count
Participants collected their hair full day, including after combing and hair-washing. Participants turned in these hair collections at each visit. The results were averaged weekly. Mean change from baseline in hair wash/shed hair count was reported at Week 12.
Time frame: At Week 12
Number of Participant in Each Response Category Based on Subject Satisfaction Questionnaire
Participant's satisfaction questionnaire was used to specifically collect the participants' feedback on the treatment regimen, the level of satisfaction and future usage. Participants were asked to complete a cosmetic acceptability questionnaire. This 10 item questionnaire had a 5-point Likert Response Scale (1=Strongly Agree; 5=Strongly Disagree).
Time frame: At Week 4,6 and 12
Number of Participants With Adverse Events (AEs)
AEs were defined as any untoward medical occurrence associated with the use of a study product in humans, whether or not considered study product related. An AE could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study product and would not imply any judgment about causality. An AE could arise with any use of the study product and with any route of administration, formulation, or dose, including an overdose. Thus, any new sign, symptom or disease, or clinically significant increase in the intensity of an existing sign, or symptom would be considered as an AE. Any new clinically relevant sign or symptom suffered by the participant, which appeared after the study procedures was reported as an AE. Any worsening in scalp dryness or itch score from baseline was also reported as an AE. The Investigator or designee had the final authorization to determine if a reaction was considered an AE.
Time frame: From start of study up to Week 12
The study was conducted in the United States from 19 May 2015 to 19 September 2015.
| Milestone | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| Started | 63 |
| Intent to treat (itt) population | 56 |
| Safety population (sp) | 61 |
| Completed | 53 |
| Not completed | 10 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Lost to follow-up | 1 |
The Investigator or a trained grader rated each participant's standardized global photographs for improvement from baseline for parameters like hair thinning, hair growth, impression of scalp hair coverage and overall perception of treatment benefit using a 1-to-7-point Likert scale. Investigator global photograph rating were assessed using 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.
| Score on a scale | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| Hair Thinning | 5.0 ± 0.9 |
| Hair Growth | 5.1 ± 0.9 |
| Impression of scalp hair coverage | 5.1 ± 0.9 |
| Overall perception of treatment benefit | 5.1 ± 0.9 |
Participants rated the parameters like appearance of hair, growth of hair, satisfaction with hairline at the front of the head, satisfaction with hair on the top of the head and satisfaction with hair overall as an overall improvement from the baseline by conducting their own assessments by looking in a mirror and evaluating improvement from baseline using a 1 to 7-point Likert scale. Each score on the individual scale ranged from 1 (minimum) to 7 (maximum), that is, (1) Entirely Disagree; (2) Mostly Disagree; (3) Somewhat Disagree; (4) Neither Agree nor Disagree; (5) Somewhat Agree; (6) Mostly Agree; (7) Entirely Agree.
| Score on a scale | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| Appearance of hair | 5.4 ± 1.2 |
| Growth of hair | 5.3 ± 1.3 |
| Satisfaction with hairline at the front of the head | 4.9 ± 1.4 |
| Satisfaction with hair on the top of the head | 5.0 ± 1.5 |
| Satisfaction with hair overall as an overall improvement | 5.2 ± 1.4 |
Participants collected their hair full day, including after combing and hair-washing. Participants turned in these hair collections at each visit. The results were averaged weekly. Mean change from baseline in hair wash/shed hair count was reported at Week 12.
| Shed Hair Count | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| Mean Change From Baseline in Shed Hair Count | 14.1 ± 21.6 |
Participant's satisfaction questionnaire was used to specifically collect the participants' feedback on the treatment regimen, the level of satisfaction and future usage. Participants were asked to complete a cosmetic acceptability questionnaire. This 10 item questionnaire had a 5-point Likert Response Scale (1=Strongly Agree; 5=Strongly Disagree).
| Participants | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| Satisfaction with appearance of hair (At Week 4) — Agree | 27 |
| Satisfaction with appearance of hair (At Week 4) — Disagree | 8 |
| Satisfaction with appearance of hair (At Week 4) — Neutral | 21 |
| Satisfaction with appearance of hair (At Week 6) — Agree | 42 |
| Satisfaction with appearance of hair (At Week 6) — Disagree | 4 |
| Satisfaction with appearance of hair (At Week 6) — Neutral | 10 |
| Satisfaction with appearance of hair (At Week 12) — Agree | 44 |
| Satisfaction with appearance of hair (At Week 12) — Disagree | 4 |
| Satisfaction with appearance of hair (At Week 12) — Neutral | 8 |
| Satisfaction with growth of hair (At Week 4) — Agree | 26 |
| Satisfaction with growth of hair (At Week 4) — Disagree | 12 |
| Satisfaction with growth of hair (At Week 4) — Neutral | 18 |
| Satisfaction with growth of hair (At Week 6) — Agree | 40 |
| Satisfaction with growth of hair (At Week 6) — Disagree | 5 |
| Satisfaction with growth of hair (At Week 6) — Neutral | 11 |
| Satisfaction with growth of hair (At Week 12) — Agree | 44 |
| Satisfaction with growth of hair (At Week 12) — Disagree | 7 |
| Satisfaction with growth of hair (At Week 12) — Neutral | 5 |
| Satisfaction with hairline at the front of the head (At Week 4) — Agree | 21 |
| Satisfaction with hairline at the front of the head (At Week 4) — Disagree | 16 |
| Satisfaction with hairline at the front of the head (At Week 4) — Neutral | 19 |
| Satisfaction with hairline at the front of the head (At Week 6) — Agree | 26 |
| Satisfaction with hairline at the front of the head (At Week 6) — Disagree | 10 |
| Satisfaction with hairline at the front of the head (At Week 6) — Neutral | 20 |
| Satisfaction with hairline at the front of the head (At Week 12) — Agree | 34 |
| Satisfaction with hairline at the front of the head (At Week 12) — Disagree | 8 |
| Satisfaction with hairline at the front of the head (At Week 12) — Neutral | 14 |
| Satisfaction with hair on the top of the head (At Week 4) — Agree | 21 |
| Satisfaction with hair on the top of the head (At Week 4) — Disagree | 16 |
| Satisfaction with hair on the top of the head (At Week 4) — Neutral | 19 |
| Satisfaction with hair on the top of the head (At Week 6) — Agree | 36 |
| Satisfaction with hair on the top of the head (At Week 6) — Disagree | 7 |
| Satisfaction with hair on the top of the head (At Week 6) — Neutral | 13 |
| Satisfaction with hair on the top of the head (At Week 12) — Agree | 37 |
| Satisfaction with hair on the top of the head (At Week 12) — Disagree | 7 |
| Satisfaction with hair on the top of the head (At Week 12) — Neutral | 12 |
| Satisfaction with hair overall as an overall improvement from the baseline (At Week 4) — Agree | 21 |
| Satisfaction with hair overall as an overall improvement from the baseline (At Week 4) — Disagree | 13 |
| Satisfaction with hair overall as an overall improvement from the baseline (At Week 4) — Neutral | 22 |
| Satisfaction with hair overall as an overall improvement from the baseline (At Week 6) — Agree | 34 |
| Satisfaction with hair overall as an overall improvement from the baseline (At Week 6) — Disagree | 5 |
| Satisfaction with hair overall as an overall improvement from the baseline (At Week 6) — Neutral | 17 |
| Satisfaction with hair overall as an overall improvement from the baseline (At Week 12) — Agree | 39 |
| Satisfaction with hair overall as an overall improvement from the baseline (At Week 12) — Disagree | 6 |
| Satisfaction with hair overall as an overall improvement from the baseline (At Week 12) — Neutral | 11 |
AEs were defined as any untoward medical occurrence associated with the use of a study product in humans, whether or not considered study product related. An AE could be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a study product and would not imply any judgment about causality. An AE could arise with any use of the study product and with any route of administration, formulation, or dose, including an overdose. Thus, any new sign, symptom or disease, or clinically significant increase in the intensity of an existing sign, or symptom would be considered as an AE. Any new clinically relevant sign or symptom suffered by the participant, which appeared after the study procedures was reported as an AE. Any worsening in scalp dryness or itch score from baseline was also reported as an AE. The Investigator or designee had the final authorization to determine if a reaction was considered an AE.
| Participants | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| Number of Participants With Adverse Events (AEs) | 4 |
Collected over From Start of Study up to Week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Minoxidil 5% Foam and Botanical Hair Solution for Men | 0/61 (0%) | 0/61 (0%) | 4/61 (6.6%) |
| Event | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| Pain (crown of head)General disorders | 1/61 |
| BronchitisRespiratory, thoracic and mediastinal disorders | 1/61 |
| Joint InjuryMusculoskeletal and connective tissue disorders | 1/61 |
| Middle ear effusionEar and labyrinth disorders | 1/61 |
SP included all participants who were enrolled and received at least one dose of study product.
| Age, Continuous(years) | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| Mean | 45.1 ± 9.7 |
| Sex: Female, Male(Participants) | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| Female | 0 |
| Male | 61 |
| Race/Ethnicity, Customized(Participants) | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 4 |
| Black or African American | 6 |
| Hispanic or Latino | 11 |
| White | 37 |
| Fitzpatrick Skin Type(Participants) | Minoxidil 5% Foam and Botanical Hair Solution for Men |
|---|---|
| II | 6 |
| III | 32 |
| IV | 18 |
| V | 5 |
Ran from May 2015 to primary completion in Nov 2015, 6 months.
Results were first posted in Aug 2023, 7 years 9 months after primary completion.
Of 61 industry-sponsored interventional studies with no phase under Alopecia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 6 months is below that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Minoxidil